Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

84 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I Study of [68Ga]Ga-Anti-CD206-sdAb for PET/CT Assessment of Protumorigenic Macrophage Presence in Solid Tumors (MMR Phase I).
Gondry O, Xavier C, Raes L, Heemskerk J, Devoogdt N, Everaert H, Breckpot K, Lecocq Q, Decoster L, Fontaine C, Schallier D, Aspeslagh S, Vaneycken I, Raes G, Van Ginderachter JA, Lahoutte T, Caveliers V, Keyaerts M. Gondry O, et al. Among authors: aspeslagh s. J Nucl Med. 2023 Sep;64(9):1378-1384. doi: 10.2967/jnumed.122.264853. Epub 2023 Jul 20. J Nucl Med. 2023. PMID: 37474271 Free PMC article. Clinical Trial.
Cemiplimab for advanced cutaneous squamous cell carcinoma in kidney transplant recipients.
Van Meerhaeghe T, Baurain JF, Bechter O, Orte Cano C, Del Marmol V, Devresse A, Doubel P, Hanssens M, Hellemans R, Lienard D, Rutten A, Sprangers B, Le Moine A, Aspeslagh S. Van Meerhaeghe T, et al. Among authors: aspeslagh s. Front Nephrol. 2022 Oct 31;2:1041819. doi: 10.3389/fneph.2022.1041819. eCollection 2022. Front Nephrol. 2022. PMID: 37675002 Free PMC article.
Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma.
Verheijden RJ, Burgers FH, Janssen JC, Putker AE, Veenstra SPGR, Hospers GAP, Aarts MJB, Hehenkamp KW, Doornebosch VLE, Verhaert M, van den Berkmortel FWPJ, Chatzidionysiou K, Llobell A, Barros M, Maria ATJ, Takeji A, García Morillo JS, Lidar M, van Eijs MJM, Blank CU, Aspeslagh S, Piersma D, Kapiteijn E, Labots M, Boers-Sonderen MJ, van der Veldt AAM, Haanen JBAG, May AM, Suijkerbuijk KPM. Verheijden RJ, et al. Among authors: aspeslagh s. Eur J Cancer. 2024 Aug;207:114172. doi: 10.1016/j.ejca.2024.114172. Epub 2024 Jun 15. Eur J Cancer. 2024. PMID: 38905818 Free article.
Associations of the gut microbiome with outcomes in cervical and endometrial cancer patients treated with pembrolizumab: Insights from the phase II PRIMMO trial.
De Jaeghere EA, Hamerlinck H, Tuyaerts S, Lippens L, Van Nuffel AMT, Baiden-Amissah R, Vuylsteke P, Henry S, Trinh XB, van Dam PA, Aspeslagh S, De Caluwé A, Naert E, Lambrechts D, Hendrix A, De Wever O, Van de Vijver KK, Amant F, Vandecasteele K, Verhasselt B, Denys HG. De Jaeghere EA, et al. Among authors: aspeslagh s. Gynecol Oncol. 2024 Nov 7;191:275-286. doi: 10.1016/j.ygyno.2024.10.020. Online ahead of print. Gynecol Oncol. 2024. PMID: 39515198
Position statement on the management of the immune checkpoint inhibitor-induced colitis via multidisciplinary modified Delphi consensus.
Desmedt V, Jauregui-Amezaga A, Fierens L, Aspeslagh S, Dekervel J, Wauters E, Peeters M, Sabino J, Crapé L, Somers M, Hoorens A, Dutré J, Lobatón T; for BIRD (Belgian IBD Research and Development); Belgian Society of Medical Oncology (BSMO); Belgian group of Digestive Oncology (BGDO); BeRS (Belgian Respiratory Society); participants of the collaborator group in the modified Delphi consensus for the Position Statement on the management of the immune checkpoint inhibitor induced colitis. Desmedt V, et al. Among authors: aspeslagh s. Eur J Cancer. 2023 Jul;187:36-57. doi: 10.1016/j.ejca.2023.03.025. Epub 2023 Mar 25. Eur J Cancer. 2023. PMID: 37116287 Review.
84 results